Fat Nugs Magazine & Beard Bros Pharms Talk Reschedule: Views from Independent Cannabis Media
As we’ve all heard, seen and read by now, the DEA is taking an unprecedented step to reschedule cannabis as a Schedule III drug (maybe). Opinions as to whether this move by the Fed is good or bad are all over the place. So instead of just releasing another article that basically states the same things everyone has already read, as a team we wanted to share our personal opinions on the possible historical move and also get Bill and Jeff Levers of Beard Bros Pharms take on it.
In Response to Calls for Cannabis Decriminalization: Evaluating the Implications of Rescheduling
Written By Tara Eveland
While HHS's recommendation is seen by the majority as a potential step forward, many cannabis industry groups are sounding the alarm and urging the public to look below the surface of yet another government promise.
One critical aspect that reform advocates underscore in this statement is that rescheduling cannabis wouldn't automatically lead to the release of current cannabis convicts or the expungement of related records. Furthermore, the unresolved issues of immigration-related consequences and eligibility for public benefits would persist. The criminalization's disproportionate impact on Black and Latino communities would continue, despite the change in scheduling